We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Eisai Company Ltd (PK) | USOTC:ESALY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 61.51 | 61.51 | 61.86 | 0.00 | 01:00:00 |
From Jul 2022 to Jul 2024
10:16 ET -- Eisai Co. and Biogen Inc. are among the most talked about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. A study of the companies' closely-watched lecanemab candidate for Alzheimer's disease showed the drug slowed cognitive decline by 27% compared with a placebo over 18 months but was associated with swelling and bleeding in the brain, with researchers recommending further, longer study. Dow Jones & Co. owns Factiva. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
November 30, 2022 10:31 ET (15:31 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Eisai (PK) Chart |
1 Month Eisai (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
